Vanguard Fiduciary Trust
ZVRA icon

Vanguard Fiduciary Trust’s Zevra Therapeutics ZVRA Stock Holding History

Vanguard Fiduciary Trust’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.74M Buy
400,208
+4,329
+1% +$48.1K ﹤0.01% 2097
2026
Q1 		$3.69M Buy
+395,879
New +$3.57M ﹤0.01% 2241

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Fiduciary Trust's ZVRA Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Zevra Therapeutics (ZVRA) stake by 1.1% in Q2 2026, buying an estimated $48.1K and bringing the position to 400,208 shares worth $5.74M. The position accounts for ﹤0.01% of the portfolio, ranked #2097.

Vanguard Fiduciary Trust first reported a position in ZVRA in Q1 2026 and has held it in 2 quarters since. 156 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Vanguard Fiduciary Trust held 400,208 shares of Zevra Therapeutics worth $5.74M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 4,329 Zevra Therapeutics shares in Q2 2026, an estimated $48.1K.
  • Zevra Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2097 holding.
  • Vanguard Fiduciary Trust first reported a position in Zevra Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 156 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.